Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02710890 · ClinicalTrials.gov registry record · Phase 2
Study to Investigate Safety and Tolerability of Intravenous Lacosamide in Children.
A Phase 2 study, sponsored by UCB Biosciences.
- Completed
- Registry status
- Phase 2
- Development phase
- 103
- Enrollment target
NCT02710890 is a Phase 2 study that has completed, run by UCB Biosciences. The registered enrollment target is 103 participants.
The verdict
NCT02710890, a Phase 2 study, has completed, sponsored by UCB Biosciences.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 103 participants
- Enrollment target
Study Summary
EP0060 is a multicenter, open-label study to evaluate the safety and tolerability of intravenous (iv) Lacosamide (LCM) in pediatric subjects \>= 1 month to \< 17 years of age with epilepsy.
Interventions
- DRUG Lacosamide
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 103 participants |
| Start Date | 2017-05-30 |
| Est. Completion | 2019-06-28 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02710890
The ClinicalTrials.gov registry entry for NCT02710890 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 103 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is UCB Biosciences, which has 39 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Lacosamide is the first listed.
NCT02710890 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02710890 about?
NCT02710890 is a clinical study titled "Study to Investigate Safety and Tolerability of Intravenous Lacosamide in Children.". EP0060 is a multicenter, open-label study to evaluate the safety and tolerability of intravenous (iv) Lacosamide (LCM) in pediatric subjects \>= 1 month to \< 17 years of age with epilepsy.
What is the current status of trial NCT02710890?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 103 participants. The study started on 2017-05-30. Estimated completion is 2019-06-28.
What interventions are being tested in trial NCT02710890?
The interventions under investigation include: Lacosamide (DRUG).
Who is sponsoring clinical trial NCT02710890?
This trial is sponsored by UCB Biosciences, which has 39 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.